title: Transplantation of two populations of stem cells to improve engraftment: WO2008060932.
abstract: BACKGROUND
  The application is in the field of haematopoietic stem cells (HSCs) and cellular therapy.
  
  
  OBJECTIVE
  It aims at improving the outcome and rate of success of HSC transplantation for treating patients with haematologic diseases, primarily following allogeneic transplantation.
  
  
  METHODS
  The patients are administered two intravenous infusions of cord blood (CB) tissue between a 2 and 24 h interval.
  
  
  RESULTS
  Patients who receive a first infusion of CB stem cells, followed by a second infusion within a 24 h interval, elicit a better outcome and rate of success of CB transplantation than patients receiving only one injection or two injections in whom the second injection was administered several days or weeks following the first one. The double infusion of CB tissue, within a 24 h interval, accelerates the time to neutrophil and platelet engraftment and immune reconstitution following myeloablative therapy.
  
  
  CONCLUSIONS
  The application claims the transplantation of at least two populations of HSCs, separated by an interval of time between 2 and 24 h, to improve the outcome of HSC transplantation for the treatment of haematologic diseases. The procedure may be extended to other types of stem cells for treating a broad range of diseases and injuries.
authors.affiliation: Dublin City University, School of Biotechnology, Glasnevin, Dublin 9, Ireland. philippe.taupin@dcu.ie
authors.forename: Philippe
authors.initials: P
authors.lastname: Taupin
mesh_terms: D001792:Blood Platelets / Q000378:metabolism; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D006402:Hematologic Diseases / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D019653:Myeloablative Agonists / Q000494:pharmacology; D009504:Neutrophils / Q000378:metabolism; D010330:Patents as Topic; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D019653:Myeloablative Agonists